Corporate | 15 April 2009 15:43
Genmab A/S /
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Summary: At Genmab A/S' Annual General Meeting held today on April 15, 2009 the
Annual Report for 2008 was approved, discharge was given to the Board of
Directors and the Management and the year's loss was carried forward. One member
of the Board of Directors retired and another member was re-elected.
PricewaterhouseCoopers was re-elected as auditor of the Company. The proposals
from the Board of Directors to change the Articles of Association were adopted.
Copenhagen, Denmark; April 15, 2009 - Genmab A/S (OMX: GEN) held its Annual
General Meeting, today April 15, 2009 at 2:00 pm at Radisson SAS Scandinavia
Hotel, Amager Boulevard 70, 2300 Copenhagen S, Denmark.
At the meeting Chairman of the Board Dr. Michael B. Widmer gave - on behalf of
the Board - a report on the Company's activities during the past year. Chief
Executive Officer and member of the Board, Lisa N. Drakeman presented plans for
the year ahead, and Chief Financial Officer David Eatwell presented the Annual
Report for 2008 endorsed by the auditors. The report was approved and discharge
was given to the Board and the Management.
It was decided that the year's loss of DKK 772 million be carried forward by
transfer to accumulated deficit, as stated in the Annual Report.
Dr. Ernst Schweizer retired from the Board and Hans Henrik Munch-Jensen was
re-elected to the Board for a three year period.
PricewaterhouseCoopers Statsautoriseret Revisionsaktieselskab A/S was reelected
as the Company's auditor.
The General Meeting adopted the proposals from the Board to change the Company's
Articles of Association, as follows:
- The proposal to remove Schedule B due to all warrants granted under the
Company's warrant programmes from 1999-2003 pursuant to Article 5 of the
Articles of Association have been exercised or have lapsed as non exercised.
- The proposal to amend Article 6 so that VP Investor Services A/S' address
'Helgeshoj Alle 61, P.O. Box 20, 2630 Taastrup' is replaced with 'Weidekampsgade
14, 2300 Copenhagen S'.
- The proposal to amend Article 8 so that the name 'OMX The Nordic Exchange
Copenhagen' is replaced with 'NASDAQ OMX Copenhagen'.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer.
Genmab's world class discovery, development and manufacturing teams are using
cutting-edge technology to create and develop products to address unmet medical
needs. Our primary goal is to improve the lives of patients who are in urgent
need of new treatment options. For more information on Genmab's products and
technology, visit www.genmab.com.
This Stock Exchange Release contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
product discovery and development, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our products,
our inability to manage growth, the competitive environment in relation to our
business area and markets, our inability to attract and retain suitably
qualified personnel, the unenforceability or lack of protection of our patents
and proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and other
factors. For a further discussion of these risks, please refer to the section
'Risk Management' in Genmab's Annual Report, which is available on
www.genmab.com. Genmab does not undertake any obligation to update or revise
forward looking statements in this Stock Exchange Release nor to confirm such
statements in relation to actual results, unless required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM);
HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM);
HuMax-TF(TM); HuMax-Her2(TM); HuMax-VEGF(TM) and UniBody(R) are all trademarks
of Genmab A/S. Arzerra(TM) is a trademark of GlaxoSmithKline.
Contact: Helle Husted, Vice President, Investor Relations, T: +45 33 44 77 30,
M: +45 25 27 47 13, E: h.husted@genmab.com
Stock Exchange Release no. 13/2009
###
News Source: NASDAQ OMX
15.04.2009 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Genmab A/S
Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of News DGAP News-Service
---------------------------------------------------------------------------